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Abstract 
Background; Although DNA methylation of colonic mucosa in ulcerative colitis (UC) 
has been suggested, the majority of published reports indicate the correlation between 
methylation of colon mucosa and occurrence of UC-related dysplasia or cancer without 
considering the mucosal inflammatory status.  
Aims; The aim of this study was to verify whether mucosal inflammation-specific DNA 
methylation occurs in the colon of UC.  
Subjects and Methods; Of 15 gene loci initially screened, 6 loci (ABCB1, CDH1, ESR1, 
GDNF, HPP1, and MYOD1) methylated in colon mucosa of UC were analyzed 
according to inflammatory status using samples from 28 surgically resected UC 
patients.  
Results; Four of six regions (CDH1, GDNF, HPP1, and MYOD1) were more highly 
methylated in the active inflamed mucosa than in the quiescent mucosa in each UC 
patient (p = 0.003, 0.0002, 0.02, and 0.048, respectively). In addition, when the 
methylation status of all samples taken from examined patients was stratified according 
to inflammatory status, methylation of CDH1 and GDNF loci was significantly higher 
in active inflamed mucosa than in quiescent mucosa (p = 0.045 and 0.002, respectively). 
Multiple linear regression analysis revealed that active inflammation was an 
independent factor of methylation for CDH1 and GDNF. DNA methyltransferase 1 and 
3b were highly expressed in colon epithelial cells with active mucosal inflammation, 
suggesting their involvement in inflammation-dependent methylation. 
Conclusions; Methylation in colonic mucosa of UC was correlated with mucosal 
inflammatory status, suggesting the involvement of methylation due to chronic active 
inflammation in UC carcinogenesis.     
 
















DNA methylation is a powerful mechanism for the suppression of gene activity. 
The reciprocal relationship between the density of methylated cytosine residues and the 
transcriptional activity of a gene has been widely documented.[1] Gene 
hypermethylation, especially, is associated with the silencing of tumor suppressor genes 
in cancer and, therefore, many kinds of cancer are acquired by aberrant methylation of 
the CpG islands within promoter regions of gene loci.[2] Thus, DNA methylation is 
largely involved in the tumorigenesis of many kinds of cancer.  
Chronic inflammation is also tightly associated with high levels of DNA 
methylation. Kanai et al. reported that DNA methylation alterations were involved in 
inflammation due to chronic hepatitis or liver cirrhosis resulting from infection with 
hepatitis B or C virus.[3] In patients with rheumatoid arthritis, CpG islands in the DR3 
gene promoter were specifically methylated to down-modulate the expression of DR3 
protein in rheumatoid synovial cells[4]. In the field of gastrointestinal tract, the 
correlation between methylation of gastric mucosa and inflammation caused by 
Helicobacter pylori (H. pylori) infection has particularly been highlighted. H. pylori 
infection potently induces aberrant DNA methylation in gastric mucosa, and 
methylation levels of a unique set of individual markers in gastric mucosa decreased 
after H. pylori eradication.[5]  
Ulcerative colitis (UC) is a relapsing non-transmural inflammatory disease that is 
restricted to the colon, with unknown etiology.[6] UC is characterized by mucosal 
ulceration, rectal bleeding, diarrhea, and abdominal pain. Also in UC, involvement of 
DNA methylation of colonic mucosa has been suggested. For example, it has been 
shown that the methylation level of the estrogen receptor 1 (ESR1) gene, which is 
known as an age-related methylation locus,[7] in nonneoplastic colorectal epithelium 
was higher in UC patients with neoplasia than in UC patients without neoplasia.[8] In 
addition, previous reports indicated that methylation of E-cadherin (CDH1) or 
hyperplastic polyposis protein 1 (HPP1) in colon mucosa of UC was an early event in 
UC-associated carcinogenesis.[9, 10] However, the majority of published reports 
correlate methylation of colonic mucosa with the occurrence of UC-related dysplasia or 
cancer without considering the inflammatory status of colonic mucosa. Chronic active 
inflammation is largely correlated with the occurrence of dysplasia or cancer in the field 
of UC as well as H.pylori associated gastritis.[5, 11] In this context, active inflammation 
in UC may be correlated with accumulation of methylation, resulting in susceptibility to 
carcinogenesis, as shown in gastric carcinogenesis correlated with H.pylori-induced 
methylation.  
In this study, therefore, we investigated the methylation status of colon mucosa 
from UC patients who underwent colectomy, and correlated it with mucosal 
inflammatory status. The aim of this study was to verify whether DNA methylation that 
is specific to mucosal inflammation also occurs in the colonic mucosa of UC.  
 Material & Methods 
Patients & tissue samples 
Colonic mucosa from 28 patients with UC who underwent total proctocolectomy 
at Okayama University Hospital between July 2004 and March 2009 were collected and 
examined. Diagnosis of UC was ascertained according to the usual clinical criteria. The 
indications for surgery of the 28 cases were as follows: 23 medication-resistant, 1 toxic 
megacolon, 2 superveniences of other disease (1 appendicitis and 1 myelodysplastic 
syndrome), 1 fulminant disease with massive bleeding, and 1 side effect of 
corticosteroids. There were no cases with evidence of UC-associated dysplasia or cancer. 
Colorectal mucosal samples were collected from active inflamed mucosa in the distal 
portion (mainly sigmoid colon), and quiescent mucosa in the proximal portion (mainly 
ascending colon) of each patient. When available, samples from active mucosa in the 
proximal portion were also collected. In addition, peripheral blood buffy coat was 
collected from 15 of the 28 UC patients. These samples were stored at −80°C until 
analysis.  
Clinical information about patients was obtained, including age, gender, disease 
duration, classification of disease as steroid-dependence or –refractory, and total amount 
of corticosteroids used. This study protocol was approved by the institutional review 
board of Okayama University Graduate School of Medicine, Dentistry, and 
Pharmaceutical Sciences. All patients provided their informed consent. 
 Methylation analysis 
The DNA in colonic tissue and peripheral blood buffy coat was extracted using 
the QIAamp DNA mini kit according to the manufacturer’s protocol (Qiagen, Valencia, 
CA). Genomic DNA was modified by sodium bisulfite to convert unmethylated 
cytosines to uracil using the EZ DNA Methylation Kit (Zymo Research, Orange, CA) 
according to the manufacturer’s protocol. The methylation status of bisulfite-converted 
DNA was determined by MethyLight, a fluorescence-based, real-time polymerase chain 
reaction (PCR) assay as described previously.[12-17]  
The CpG loci examined were the promoter regions of glycoprotein/ATP binding 
cassette sub-family B member 1 (ABCB1), APEX nuclease (multifunctional DNA repair 
enzyme) 1 (APEX), CDH1, cyclin-dependent kinase inhibitor 2A (CDKN2A, p16), 
claudin 1 (CLDN1), β-catenin (CTNNB1), damage-specific DNA binding protein 1 
(DDB1), ESR1, glial cell derived neurotrophic factor (GDNF), 
O-6-methylguanine-DNA methyltransferase (MGMT), myogenic differentiation 1 
(MYOD1), HPP1, mut L homolog 1 (MLH1), SMAD family member 2 (SMAD2), and 
suppressor of cytokine signaling 1 (SOCS1). The promoter region of β-actin (ACTB) 
was also analyzed to normalize for input DNA. For the analysis of MethyLight, primers 
and probes, which generally span 7 to 10 CpG dinucleotides, were specifically designed 
to bind to bisulfite-converted DNA of these gene loci. The primer and probe sequences 
for 6 genes that exhibited positive methylation results in the primary screening 
experiments are shown as follows (the forward PCR primer, TaqMan probe, and the 
reverse PCR primer, respectively): 
ABCB1 (TCGGGTCGGGAGTAGTTATTTG, 
6FAM5’-ACGCTATTCCTACCCAACCAATCAACCTCA-3’TAMRA, 





TTCACCTACCGACCACAACCA); ESR1 (GGCGTTCGTTTTGGGATTG, 
6FAM5’-CGATAAAACCGAACGACCCGACGA-3’TAMRA, 
GCCGACACGCGAACTCTAA); GDNF (CGGTAGTTGTCGTTGAGTCGTTC, 
6FAM5’-CGCGCGTCGCGCTCTTAACTAAAA-3’TAMRA, 
AACAACCGCCGCTACTTTAAATA); MYOD1 (GAGCGCGCGTAGTTAGCG, 
6FAM5’-CTCCAACACCCGACTACTATATCCGCGAAA-3’TAMRA, 
TCCGACACGCCCTTTCC); HPP1 (TTTTTTTTTCGGACGTCGTTG, 
6FAM5’-AATTACCGAAAACATCGACCGA-3’TAMRA, 
CCTCTACATACGCCGCGAAT).[12, 15-18] The primer and probe sequences for the 
other 9 regions were described previously.[16] The specificity of the reactions for 
methylated DNA was confirmed separately using SssI-treated genomic DNA as the 
methylated control.  
For data presentation, the percentage of methylated references (PMR) was 
indicated. PMR at a specific locus was calculated by dividing the GENE:ACTB ratio of 
a sample by that of SssI-treated genomic DNA and multiplying by 100.[13, 14] 
Immunohistochemistry 
Immunohistochemistry of colonic mucosa for three types of DNA 
cytosine-5-methyltransferases (DNMT1, DNMT3a and DNMT3b), which play roles in 
the establishment and regulation of tissue-specific patterns of methylated cytosine 
residues, was performed. Sections (5 μm thick) of formalin-fixed, paraffin embedded 
tissues from three UC patients and one patient with colorectal cancer were 
deparaffinized in xylene and rehydrated in a series of graded ethanol. After washing 
three times with phosphate-buffered saline (PBS), slides were placed in a steam cooker 
filled with 10 mmol sodium citrate buffer, pH 6.0, for 12 min for antigen retrieval. After 
washing three times with PBS, endogeneous peroxidase activity was blocked by 
incubating sections with 3% H2O2. After treatment with a serum free dilution for 30 
minutes to block nonspecific protein binding, mouse monoclonal antibody for Dnmt1 
(IMG-261A mouse; Imgenex, San Diego, CA), Dnmt3a (39206 mouse; Active Motif, 
Carlsbad, CA) or Dnmt3b (52A1018 mouse; Abcam, Cambridge, UK) was applied and 
incubated at 4°C overnight. After washing three times with PBS and reaction with 
biotinylated anti-mouse antibody for 5 minutes, antigen-antibody complexes were 
visualized using a streptavidin-horseradish peroxidase conjugate (LSAB kit; Dako, 
Carpenteria, CA) with diaminobenzidine as a chromogen. Slides were counterstained 
with Mayer’s hematoxylin for 2 minutes. For the negative control, PBS replaced the 
primary antibody. Lymphocytes on the same slide were used as an internal positive 
control for DNMT immunoreactivity.[19, 20] We assessed DNMT immunoreactivity 
only in the nucleus using the staining intensity and the proportion of positive cells. The 
histological sections were independently evaluated, and relative intensities and 
proportions of the signals were estimated as weakly positive to strongly positive.  
Statistical analysis 
The differences in CpG island methylation levels (the PMR of ABCB1, CDH1, 
ESR1, HPP1, MYOD1, or GDNF) between proximal colon and distal colon mucosa of 
each UC patient was evaluated using the Wilcoxon signed-ranks test. The differences in 
methylation levels between quiescent and active colon mucosa of patients with UC was 
evaluated using the Mann-Whitney’s U test. The association between PMR and clinical 
characteristics was evaluated using multiple linear regression analysis. These analyses 
were carried out using SAS version 9.1 (SAS Institute, Cary, NC, USA). All P-values 
were two-tailed and considered significant when less than 0.05.  
 
Results 
 Clinical characteristics of patients 
The methylation status of 28 UC patients who underwent colectomy was 
examined. Of these, 21 patients had active inflamed mucosa in the distal colon and 
quiescent mucosa in the proximal colon, and 13 patients had active inflamed mucosa 
both in the distal and proximal colon. All patients had active inflamed mucosa in the 
distal colon, and 6 patients had both active and quiescent portions in the proximal colon. 
Clinical characteristics of these patients are shown in Table 1.  
Methylation status of colonic mucosa in each UC patient  
     To examine the methylation levels of colonic mucosa in UC patients according to 
the inflammatory status, we screened the methylation status of 15 gene loci (ABCB1, 
APEX, CDH1, CDKN2A, CLDN1, CTNNB1, DDB1, ESR1, GDNF, MGMT, MYOD1, 
HPP1, MLH1, SMAD2, and SOCS1) that were methylated in colon mucosa in previous 
reports.[7-10, 16, 21-25] Among these, 6 (ABCB, CDH1, ESR1, GDNF, HPP1, and 
MYOD1) loci exhibited methylation in colonic mucosa of UC and were examined 
according to inflammatory status. First, we compared methylation levels between distal 
active inflamed mucosa and proximal quiescent mucosa in each of 21 patients. Four 
genes (CDH1, GDNF, HPP1, and MYOD1) showed significantly higher methylation 
levels in active inflamed distal colon than in quiescent proximal colon (p = 0.003, 0.02, 
0.048, and 0.0002, respectively) (Figure 1). Two other genes (ABCB1 and ESR1) did 
not show significant differences between the proximal and distal colon mucosa, but the 
methylation level of ESR1 was slightly higher in the active inflamed distal colon than in 
quiescent proximal colon (p = 0.06).  
After examining methylation changes in each patient separately, the patients were 
divided into two groups: patients with a large overall increase in methylation (n = 4) and 
patients with a small overall increase in methylation (n = 17). The group with a large 
increase in methylation showed more than two times the PMR values in the active 
mucosa compared to the values in the quiescent mucosa for three or more of the six loci 
examined. This group tended to have longer disease duration and a higher level of total 
corticosteroid use, although significant differences were not observed due to the small 
number of included patients (p = 0.06 and p = 0.06, respectively). Although no patients 
displayed increased methylation in all six loci, two patients exhibited very large 
increases (average 2.89 fold and 2.41 fold) in several loci. Both of these patients had 
disease duration of more than thirty years. 
To examine the difference in methylation according to location, we then analyzed 
the methylation status of six genes between the proximal and distal colon of 13 patients, 
both of which exhibited active inflammation. In this case, only CDH1 showed a 
significantly higher methylation level in distal colon than in proximal colon (p = 0.03) 
(Figure 2). The other five genes showed no differences between the proximal and distal 
colon mucosa.  
Because many inflammatory cells, mainly comprised of white blood cells (WBC), 
infiltrate active inflamed colonic mucosa of UC, their presence may inflate the 
methylation status of inflamed colonic mucosa. To estimate the contribution from 
infiltrating cells in UC colonic mucosa to the amount of methylation observed, we 
determined the methylation status of peripheral blood WBC DNA from buffy coat in 15 
of the 28 patients. The PMRs of peripheral blood WBC DNA were much lower than 
those of colon tissue DNA in five loci except ABCB1 (average PMRs of peripheral 
blood WBC DNA vs. colon tissue DNA; CDH1: 0.59 vs. 4.12, ESR1: 0.24 vs. 4.39, 
HPP1: 0.05 vs. 2.54, MYOD1: 0.22 vs. 3.30, GDNF: 0.15 vs. 4.77). In ABCB1, the 
PMRs of peripheral blood WBC were more than half that of colonic mucosa (average 
PMRs of peripheral blood WBC DNA vs. colon tissue DNA; 24.4 vs 42.4). Thus, the 
effects of migrating WBC on the methylation status of colonic mucosa were small 
except for the ABCB1 locus. These results suggest that the methylation status of several 
gene loci in colon epithelial cells of UC differs according to the mucosal inflammatory 
status in each UC patient.  
Specific methylation for active inflammation of UC 
To identify specific methylation for active inflammation of UC, the methylation 
status of all samples was stratified according to mucosal inflammatory status. The 
methylation status of active inflamed colonic mucosal samples (41 samples) was 
compared with that of quiescent mucosal samples (21 samples) from all 28 patients 
(Figure 3). This analysis showed that methylation of CDH1 and GDNF loci was 
significantly higher in active inflamed mucosa than in quiescent colon mucosa (p = 
0.045 and 0.002, respectively). There were no significant differences in the methylation 
levels of four other gene loci (ABCB1, ESR1, HPP1, and MYOD1) between active 
inflamed colon mucosa and quiescent colon mucosa. 
Because it has been reported that six genes analyzed in this study are methylated 
due to various reasons, particularly in an age-dependent manner,[7, 26, 27] we 
examined whether methylation of CDH1 and GDNF was unequivocally caused by 
mucosal inflammation via multiple linear regression analysis. Six parameters including 
age, gender, disease duration, total amount of corticosteroids, clinical course 
(steroid-dependence or –refractory), and inflammatory status (active or quiescent) were 
used for the analysis (Table 2). The results indicated that active inflammation was an 
independent factor for methylation of both CDH1 and GDNF loci (p = 0.02 and 0.0006, 
respectively). In addition, disease duration and total amount of steroids were significant 
factors for methylation of GDNF (p = 0.02 and 0.01, respectively). Although a similar 
analysis was performed for both patient groups with a large overall increase in 
methylation and with a small overall increase in methylation, no other significant 
factors were identified. These results suggest that there are gene loci that are specifically 
methylated by active mucosal inflammation caused by UC.  
Immunohistochemistry of DNA methyltransferases  
Because we found that methylation specifically occurred in inflamed mucosa of 
UC, we examined the expression of three types of DNA methyltransferases (DNMT1, 
DNMT3a and DNMT3b). DNMT1 is the main enzyme responsible for copying the 
methylation pattern after each round of DNA replication.[28] DNMT3a and DNMT3b 
encode DNA methyltransferases primarily involved in de novo methylation rather than 
maintenance of methylation.[29] Immunohistochemistry for DNMTs was performed in 
active and quiescent mucosa of three UC patients and in normal colon mucosa of one 
patient who had colorectal cancer without UC. DNMT1 was more highly expressed in 
active inflamed UC colon mucosa than in quiescent UC colon mucosa (Figures 4A and 
4D). The DNMT1 expression level in normal colon mucosa from the colorectal cancer 
patient was similarly weak to that of quiescent UC mucosa (Figures 4G). DNMT3b 
showed an expression pattern similar to that of DNMT1 (Figures 4C, 4F and 4I), 
although the immunoreactiviy of DNMT3b was slightly weaker than that of DNMT1. In 
contrast, DNMT3a was negative in active inflamed mucosa, quiescent mucosa, and 
mucosa without UC (Figures 4B, 4E and 4H). These results suggest that active 
inflammation causes DNA methylation through activation of DNMT1 and DNMT3b.  
 
Discussion 
The data presented here demonstrate that methylation levels of several 
gene-associated CpG islands were substantially higher in active inflamed colon mucosa 
than in quiescent colon mucosa in UC patients. Particularly, CDH1 and GDNF loci 
were significantly more highly methylated in active colon mucosa. Finally, increased 
methylation in inflamed UC may result from the upregulation of DNMT1 expression.  
The phenomenon that methylation in colon mucosa of UC is correlated with 
active inflammation supports the observations associated with natural history of UC. In 
contrast to mutation, methylation is prevalent in nonneoplastic cells and is reversible. In 
fact, methylation in gastric nonneoplastic mucosa caused by H.pylori can be reversed by 
eradication of the bacteria.[5] In UC, appropriate medication can allow recovery of 
actively inflamed mucosa into quiescent mucosa. In addition, the mucosal inflammatory 
status of different colonic locations at different times can vary in UC patients. Thus, 
these disease properties of UC may be correlated with the reversible character of DNA 
methylation.  
Although there have been studies reporting increased DNA methylation in 
colonic mucosa of UC, the majority correlated methylation with the occurrence of 
UC-related dysplasia/cancer without considering the mucosal inflammatory status.[7-10, 
24, 30, 31] Issa et al. reported that methylation of several gene-associated CpG islands 
was present in the normal-appearing epithelium from UC patients with high-grade 
dysplasia or cancer.[7] Tominaga et al.[8] analyzed ESR1 methylation in different parts 
of the large intestine in UC patients with and without neoplasia and proved that ESR1 
methylation was correlated with an increased risk of developing neoplasia. These 
reports suggest that the methylation levels of colonic mucosa of UC vary according to 
the presence or absence of neoplasia and that accumulation of methylation finally 
induces cancer development, as shown in H.pylori related gastritis[11, 32-35] and 
termed ‘epigenetic field cancerization’.[34] In addition to this evidence, we demonstrate 
that methylation of colonic mucosa is largely correlated with active inflammation of the 
mucosa. A clinical study indicated that the severity of microscopic inflammation over 
time is an independent risk factor for developing advanced colorectal neoplasia among 
patients with long-standing UC.[36] This clinical feature may be due to the 
accumulation of methylation caused by active inflammation, culminating as epigenetic 
field cancerization of UC.  
We selected 15 candidate gene loci and found methylation in 6 loci in colonic 
mucosa of UC patients. Expression of ABCB1 in the intestinal tract has an important 
role in the pharmacokinetics of drugs used to treat UC, such as corticosteroids, and 
methylation of this locus was reported in colonic mucosa of UC.[21] E-cadherin is 
encoded by the CDH1 gene, which is located on chromosome 16q22. Azarschab et al. 
found methylation of CDH1 to be associated with dysplasia of UC.[22] Issa et al.[7] 
reported that ESR1 and MYOD1, which are affected by age-related methylation in 
colorectal epithelium, were extensively methylated not just in the neoplastic mucosa but 
also in the normal-appearing epithelium from UC patients with high-grade dysplasia or 
cancer. Methylation of HPP1, found by screening hyperplastic polyps and normal 
mucosa, was shown to be a relatively common early event in UC-associated 
carcinogenesis.[9] GDNF expression is up-regulated in inflammatory bowel disease and 
experimental colitis, and this neurotrophic factor has strong anti-apoptotic effects on 
colonic epithelial cells.[23] Methylation of GDNF was observed in a subset of 
colorectal cancer.[16] These loci were methylated to some extent in colon mucosa of 
UC, whereas the other 9 loci (APEX, CDKN2A, CLDN1, CTNNB1, DDB1, MLH1, 
MGMT, and SOCS1, SMAD2) were not methylated. The results suggest that methylation 
caused by inflammation of UC is locus specific, although the mechanism is unknown. 
However, such locus specific methylation has also been reported in H. pylori-related 
gastric inflammation.[11, 35]  
Our results indicate that active inflammation was the strongest determinant for the 
PMRs of both CDH1 and GDNF. E-cadherin (encoded by CDH1) mediates cell-cell 
adhesion in colon epithelium. A previous report observed a substantial decrease in 
membranous E-cadherin expression, with a concomitant increase in cytoplasmic 
E-cadherin expression, in UC-related cancer.[37] The decrease in membranous 
E-cadherin may be an early event in UC-related tumorigenesis because decreased 
membranous E-cadherin expression can also be detected in UC-affected, nondysplastic 
colonic mucosa.[38] In addition, a previous study showed that CDH1 promoter 
methylation might be involved in neoplastic progression from chronic inflammation to 
colorectal cancer in patients with long-standing UC.[22] Taken together, methylation of 
CDH1 correlates with active inflammation of colonic mucosa and may be correlated 
with a decrease in membranous E-cadherin. As a result, accumulation of methylation at 
this locus may be involved in UC-related carcinogenesis.  
On the other hand, GDNF family ligands and their receptors activate the Ret 
signaling pathway and regulate cell survival and proliferation.[39] In addition, Ret 
expression compromises neuronal cell survival in the colon.[40] Therefore, it has been 
considered that GDNF is a novel member in the set of protective mucosal factors.[23] In 
this context, dysregulation of GDNF can lead to down-regulation of Ret expression and 
may finally result in failure of colonic mucosal protection. Thus, methylation of the 
GDNF locus may itself be correlated with severe inflammation in colon mucosa of UC 
through loss of mucosal protection. Moreover, neoplastic progression may be facilitated 
by the loss of mucosal protection involving GDNF. 
The deregulation of DNMT expression (mainly DNMT1 and DNMT3b) has been 
shown to contribute to tumorigenesis and tumor suppressor gene hypermethylation[41]. 
Therefore, our results that DNMT1 and DNMT3b were highly expressed in active 
inflamed mucosa suggest the correlation between active inflammation of UC and 
occurrence of dysplasia/cancer. In particular, DNMT1 functions as a maintenance 
DNMT enzyme and is responsible for accurately replicating genomic DNA methylation 
patterns during cell division.[42] DNMT1 is necessary and sufficient to maintain global 
methylation and aberrant CpG island methylation in human cancer cells.[43] A previous 
study reported that oxidative stress, caused by anticancer agents and ionizing radiation, 
increased both DNMT1 protein levels as well as overall global DNA methylation in 
colon cancer cells.[42] In turn, inflammation in active UC was strongly correlated with 
oxidative stress.[45-47] Thus, high expression of DNMT1 in accordance with active 
mucosal inflammation may be induced by oxidative stress, and this aberrant expression 
of DNMT1 may increase methylation of several gene loci.  
There are limitations to this study. First, we analyzed methylation of fifteen 
candidate genes and did not perform a comprehensive analysis. To more rigorously 
examine methylation correlated with inflammation of UC, a comprehensive approach is 
required. Second, we could not directly investigate the influence of infiltrating WBC on 
the analysis of methylation of colonic mucosa. To compensate for this limitation, we 
determined the methylation status of peripheral blood WBC in this study, following a 
protocol similar to that in a report examining the methylation of gastric mucosa with 
infiltrating WBC due to H. pylori infection.[48] Although the precedent indicated that 
the influence of WBC could be ignored, the effect of a small fraction of infiltrating cells 
other than WBC may exist. Third, we could not confirm the expression of DNMTs by 
PCR or Western blotting analysis. Because DNMTs are expressed in the infiltrating 
inflammatory cells, such methods were considered inappropriate for evaluating the 
expression of DNMTs in colonic epithelium. Finally, the analyzed specimens were all 
taken from patients who underwent colectomy. These patients usually have a more 
severe clinical course and may be different from UC patients who go through a usual 
clinical course.  
In conclusion, we showed that there are loci methylated in accordance with 
mucosal inflammation in colonic mucosa of UC patients. In particular, increased 
methylation of CDH1 and GDNF is specific to mucosal active inflammation. Our 
results may indicate a potential epigenetic mechanism underlying mucosal inflammation 
















The differences in methylation levels between the quiescent proximal and active 
distal colon mucosa of each UC patient. (n = 21) 
Wilcoxon signed-ranks test 
Figure 2 
The differences in methylation levels between active proximal and active distal 
colon mucosa of each UC patient. (n = 13) 
Wilcoxon signed-ranks test 
Figure 3 
The differences in methylation levels between the quiescent (n=21) and active 
(n=41) colon mucosa from all examined UC patients. Mann-Whitney’s U test 
Figure 4 
Immunohistochemical staining of DNA methyltransferase 1 (DNMT1), DNA 
methyltransferase 3a (DNMT3a) and DNA methyltransferase 3b (DNMT3b). DNMT1 
expression was strong in active inflamed mucosa of UC patients (A), weak in quiescent 
mucosa of UC (D), and weak in normal appearing mucosa from a colorectal cancer 
patient (G). DNMT3b showed an expression pattern similar to that of DNMT1, 
although the intensity of DNMT3b in active inflamed mucosa was slightly weaker than 
that of DNMT1 (C, F, and I). DNMT3a was negative in active inflamed mucosa of UC, 
quiescent mucosa of UC, and normal appearing mucosa from a colorectal cancer patient 
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